Novel Antihyperglycemics and their Uses in Type 2 Diabetes Mellitus and Beyond.
by Zabrina Y.O. Abolarin, BS, 2024 PharmD Candidate, Angelica DiPrizio, BS, 2023 PharmD Candidate, Jessica R. Schwartzwald, BS, 2024 PharmD Candidate, Dagmara P. Zajac, BS, 2023 PharmD Candidate
"While United States guidelines for the treatment of type 2 diabetes mellitus (T2DM) have not undergone a major change in the most recent update, the number of treatments and the amount of research into novel approaches are in constant flux. Currently, there are 11 antihyperglycemic classes used in the treatment of T2DM. The newer SGLT-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), adjunct to lifestyle modifications, help reduce hemoglobin A1c and maintain glycemic control; however, recent investigations for their use beyond T2DM have earned them a place in the treatment of heart failure, chronic kidney disease, and obesity management."
Keywords: Empagliflozin, Dapagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Canagliflozin, Glycated Hemoglobin A, Glucagon-Like Peptide-1 Receptor, Ertugliflozin, Creatinine, Liraglutide, Cardiovascular Diseases, Blood Pressure, Semaglutide, Arterioles, Diabetic Nephropathies, Fasciitis, Necrotizing, Glomerular Filtration Rate, Glycemic Control, Hyperkalemia, Insulin Resistance, Natriuresis, United States Food and Drug Administration, Urine, Risk Factors, Clinical Protocols, Hospitalization, Dyslipidemias, Hypoglycemia, Amputation, Retinal Diseases, Glucose, Obesity
Download PDF
2022 September/October Table of Contents
"While United States guidelines for the treatment of type 2 diabetes mellitus (T2DM) have not undergone a major change in the most recent update, the number of treatments and the amount of research into novel approaches are in constant flux. Currently, there are 11 antihyperglycemic classes used in the treatment of T2DM. The newer SGLT-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), adjunct to lifestyle modifications, help reduce hemoglobin A1c and maintain glycemic control; however, recent investigations for their use beyond T2DM have earned them a place in the treatment of heart failure, chronic kidney disease, and obesity management."
Keywords: Empagliflozin, Dapagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Canagliflozin, Glycated Hemoglobin A, Glucagon-Like Peptide-1 Receptor, Ertugliflozin, Creatinine, Liraglutide, Cardiovascular Diseases, Blood Pressure, Semaglutide, Arterioles, Diabetic Nephropathies, Fasciitis, Necrotizing, Glomerular Filtration Rate, Glycemic Control, Hyperkalemia, Insulin Resistance, Natriuresis, United States Food and Drug Administration, Urine, Risk Factors, Clinical Protocols, Hospitalization, Dyslipidemias, Hypoglycemia, Amputation, Retinal Diseases, Glucose, Obesity
Download PDF
2022 September/October Table of Contents